The first global approval of guselkumab in the USA has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.  

In November 2017, Guselkumab (Tremfya™), developed by Janssen Biotech Inc, was also approved in Canada for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.[1]

“A new and effective treatment option, like TREMFYA, is always welcome news for the psoriasis patient community,” said Kathryn Andrews-Clay, Executive Director, Canadian Association of Psoriasis Patients. “Psoriasis not only takes a tremendous toll on a patient’s body as dry, flaky skin, which characterizes the disease can appear on the scalp, hands, feet and more, it can also impact a patient’s confidence and mental health.” [1]

For further information related to the first approval of guselkumab please visit Drugs, or to learn more about the overall development of guselkumab across all indications visit AdisInsight.

Image credit:  Ivelin Radkov / Fotolia

Leave a Reply